Anti-hepatitis C virus activity of geranylgeranylacetone treatment in hepatitis C-infected patients

DOI 機関リポジトリ HANDLE
  • YAMAGUCHI Tohei
    Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University
  • ICHIKAWA Tatsuki
    Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University
  • TAKESHITA Shigeyuki
    Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University
  • TAURA Naota
    Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University
  • MIYAAKI Hisamitsu
    Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University
  • MURAOKA Toru
    Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University
  • SHIBATA Hidetaka
    Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University
  • HONDA Takuya
    Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University
  • HAMASAKI Keisuke
    Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University
  • KATO Yuji
    Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University
  • TAKESHIMA Fuminao
    Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University
  • NAKAO Kazuhiko
    Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University

この論文をさがす

抄録

Background. Geranylgeranylacetone (GGA), which is an isoprenoid compound, has been used orally as an antiulcer drug in Japan. GGA induces antiviral gene expression by stimulating the formation of interferon-stimulated gene factor 3 in human hepatoma cells. This study verified the anti-hepatitis C virus (HCV) activity of GGA in chronic hepatitis C-infected patients. Methods. The present prospective study included 20 consecutive anti-HCV antibody-positive, HCV-genotype 1b, and chronic gastritis patients who visited Nagasaki University Hospital between January 1999 and December 1999. GGA (150 mg per day, which is the dose generally used for chronic gastritis) was taken orally for four weeks. We evaluated HCV-RNA titers and other clinical parameters at pretreatment, posttreatment, and at the endpoint of the study. Pretreatment was the beginning point of GGA treatment. Posttreatment was the termination point of GGA treatment. The endpoint was the point four weeks after the posttreatment point. Results. All patients completed four weeks of GGA treatment and four weeks of observation. HCV-RNA titers at postpoint were not significantly diminished compared to those at pretreatment. However, HCV-RNA titers were significantly diminished at endtreatment compared to pretreatment. Unfortunately, we did not observe a case with no titer of HCV-RNA. Alanine aminotransferase values and other parameters were not affected by GGA treatment. Conclusion. GGA has anti-HCV activities in chronic hepatitis C-infected patients. In the future, it will be necessary to examine the clinical effectiveness of the combination of treatment with both GGA and interferon in HCV patients.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ